Myovant Sciences is dedicated to advancing healthcare through innovative treatments and technologies that address critical patient needs across various medical fields, including psychiatry, neurology, oncology, urology, women's health, rare diseases, and cell and gene therapy. The company emphasizes the importance of a technology-driven approach to drug discovery, development, and commercialization, aiming to enhance the efficiency and speed of these processes. By leveraging life-sciences expertise, Myovant seeks to deliver patient-first solutions that can significantly improve health outcomes.

The company's diverse pipeline includes both preclinical and clinical programs that target high unmet medical needs. Myovant Sciences is committed to fueling breakthroughs in healthcare by integrating advanced technologies into their research and development efforts. This focus on innovation not only aims to expedite the delivery of new treatments but also strives to ensure that these solutions are tailored to the specific needs of patients, ultimately enhancing their overall well-being.

United States

We aspire to be the leading healthcare company focused on redefining care for women’s health and prostate cancer. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer. We strive to improve the lives of millions of people, while building an innovative, dynamic, and collaborative company where employees thrive.

Cancer

Urogenital Diseases

Myovant Sciences

Endometriosis

Reproductive disease

Uterine disease

Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces production of ovarian estradiol, a hormone known to stimulate the growth of uterine fibroids and endometriosis, and testicular testosterone, a hormone known to stimulate the growth of prostate cancer.&nbsp;Myovant&nbsp;is developing a relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for women with uterine fibroids and for women with endometriosis. Myovant&nbsp;is also developing relugolix as a monotherapy tablet (120 mg once daily) for men with advanced prostate cancer.

MYFEMBREE (Relugolix) (GnRH receptor antagonist)

Prostate cancer

Prostate disease

Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces testicular testosterone, a hormone known to stimulate the growth of prostate cancer, and ovarian estradiol, a hormone known to stimulate the growth of uterine fibroids and endometriosis.&nbsp;Relugolix monotherapy tablet (120 mg) is under regulatory review in the&nbsp;U.S.&nbsp;for men with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in&nbsp;Europe&nbsp;and the&nbsp;U.S.&nbsp;for women with uterine fibroids and is under development for women with endometriosis.

ORGOVYX (Relugolix) (GnRH receptor antagonist) 

Benign tumor

Uterine fibroids

Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces ovarian estradiol, a hormone known to stimulate the growth of uterine fibroids and endometriosis, and testicular testosterone, a hormone known to stimulate the growth of prostate cancer.&nbsp;Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in&nbsp;Europe&nbsp;and the&nbsp;U.S.&nbsp;for women with uterine fibroids and is under development for women with endometriosis.&nbsp;Relugolix monotherapy tablet (120 mg) is under regulatory review in the&nbsp;U.S.&nbsp;for men with advanced prostate cancer.

Myovant Sciences

Company Details